Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
तुलना करने के लिए मीट्रिक्स | TLPH | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधTLPHपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −0.8x | −5.9x | −0.7x | |
PEG अनुपात | −0.01 | 0.00 | 0.00 | |
क़ीमत/बुक | 1.2x | 2.8x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 41.9x | 3.2x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 139.8% | 47.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 16.9% | 7.5% | अनलॉक करें |